Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 150 of 218 entries
View as:

LEO 29102 Single and Multiple Dose Study by Dermal Application

Phase: N/A Priority: Normal
NCT ID: NCT00891709 Org: User:
Start: 03/31/09 End: 06/30/09 Due: 06/30/10

Efficacy and Safety of Calcipotriol Plus Hydrocortisone Ointment in Psoriasis Vulgaris on the Face and Skin Folds

Phase: N/A Priority: Normal
NCT ID: NCT00691002 Org: User:
Start: 05/31/08 End: 01/31/10 Due: 01/31/11

Tralokinumab Monotherapy for Moderate to Severe Atopic Dermatitis - ECZTRA 1 (ECZema TRAlokinumab Trial no. 1)

Phase: N/A Priority: Normal
NCT ID: NCT03131648 Org: User:
Start: 05/30/17 End: 10/10/19 Due: 10/10/20

A Plaque Test Study With LEO 35299 in Psoriasis Vulgaris

Phase: N/A Priority: Normal
NCT ID: NCT01580488 Org: User:
Start: 04/30/12 End: 06/30/12 Due: 06/30/13

A Psoriasis Plaque Test Comparing Products for the Treatment of Psoriasis Vulgaris

Phase: N/A Priority: Normal
NCT ID: NCT01043224 Org: User:
Start: 01/31/10 End: 03/31/10 Due: 03/31/11

Pharmacokinetics of LEO 43204 Gel in Actinic Keratosis Administered Under Maximal Use Conditions

Phase: N/A Priority: Normal
NCT ID: NCT02424305 Org: User:
Start: 05/31/15 End: 07/31/15 Due: 07/31/16

Safety and Efficacy of Escalating Doses of LEO 43204 Applied Once Daily for Two Consecutive Days on Approximately 250 cm2 on Trunk and Extremities in Subjects With Actinic Keratosis

Phase: N/A Priority: Normal
NCT ID: NCT02120456 Org: User:
Start: 05/31/14 End: 05/31/15 Due: 05/31/16

Vaccine Responses in Tralokinumab-Treated Atopic Dermatitis - ECZTRA 5 (ECZema TRAlokinumab Trial No. 5)

Phase: N/A Priority: Normal
NCT ID: NCT03562377 Org: User:
Start: 07/13/18 End: 11/22/19 Due: 11/22/20

Risk of Squamous Cell Carcinoma on Skin Areas Treated With Ingenol Mebutate Gel, 0.015% and Imiquimod Cream, 5%

Phase: N/A Priority: Normal
NCT ID: NCT01926496 Org: User:
Start: 09/11/13 End: 07/11/19 Due: 07/11/20

A Plaque Test Comparing the Anti-psoriatic Effect of Marketed Products for Topical Use for Psoriasis Vulgaris

Phase: N/A Priority: Normal
NCT ID: NCT00845481 Org: User:
Start: 01/31/09 End: 05/31/09 Due: 05/31/10

Cromoglicate in Psoriasis

Phase: N/A Priority: Normal
NCT ID: NCT01722812 Org: User:
Start: 11/30/12 End: 05/31/13 Due: 05/31/14

Efficacy of Twice Daily Application of LEO 124249 Ointment 30 mg/g for 12 Weeks on Eyebrow Alopecia Areata.

Phase: N/A Priority: Normal
NCT ID: NCT03325296 Org: User:
Start: 10/30/17 End: 05/16/18 Due: 05/16/19

LP0058-1005 - A Open-Label, Four-Way Crossover and Food-Effect Study of LEO 32731 in Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT02126371 Org: User:
Start: 05/31/14 End: 01/31/15 Due: 01/31/16

Efficacy and Safety of Delgocitinib Cream in Discoid Lupus Erythematosus.

Phase: N/A Priority: Normal
NCT ID: NCT03958955 Org: User:
Start: 07/09/19 End: 04/30/20 Due: 04/30/21

An Irritation Study With New Calcipotriol Ointment Formulations in Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT01105234 Org: User:
Start: 04/30/10 End: 05/31/10 Due: 05/31/11

Efficacy and Safety of Fucicort® Lipid Cream Compared to Combination Treatment With Fucidin® Cream Followed by Betamethasone (Lianbang Beisong®) Cream and Fucicort® Lipid Cream Vehicle in Clinically Infected Atopic Dermatitis/Eczema

Phase: N/A Priority: Normal
NCT ID: NCT03395132 Org: User:
Start: 07/31/18 End: 05/09/19 Due: 05/09/20

A Short-contact Plaque Test Study With Daivobet® Gel in Psoriasis Vulgaris

Phase: N/A Priority: Normal
NCT ID: NCT01607853 Org: User:
Start: 06/30/12 End: 10/31/12 Due: 10/31/13

Efficacy and Safety of Brodalumab in Adolescents From 12 to 17 Years of Age With Moderate-to-severe Plaque Psoriasis

Phase: N/A Priority: Normal
NCT ID: NCT04305327 Org: User:
Start: 12/07/22 End: 05/05/23 Due: 05/05/24

Safety and Tolerability of LEO 138559 in Healthy Subjects and Subjects With Atopic Dermatitis

Phase: N/A Priority: Normal
NCT ID: NCT03514511 Org: User:
Start: 05/07/18 End: 03/02/21 Due: 03/02/22

Safety and Efficacy of LEO 80185 Topical Suspension in Adolescent Subjects (Aged 12 to 17) With Scalp Psoriasis

Phase: N/A Priority: Normal
NCT ID: NCT01083758 Org: User:
Start: 04/30/10 End: 10/31/12 Due: 10/31/13

Efficacy and the Tolerability of the Sequential Application of Two Marketed Products in Patients With Acne Vulgaris

Phase: N/A Priority: Normal
NCT ID: NCT01461655 Org: User:
Start: 11/30/11 End: 05/31/12 Due: 05/31/13

Safety and Efficacy of Doses of LEO 43204 Once Daily for Two Consecutive Days on Full Balding Scalp in Subjects With Actinic Keratosis

Phase: N/A Priority: Normal
NCT ID: NCT02100813 Org: User:
Start: 05/31/14 End: 03/31/15 Due: 03/31/16

A Trial to Evaluate the Efficacy and Safety of Different Doses of LEO 138559 in Adults With Moderate-to-severe Atopic Dermatitis

Phase: N/A Priority: Normal
NCT ID: NCT05923099 Org: User:
Start: 09/20/23 End: 04/09/25 Due: 04/09/26

LEO 90100 Twice Weekly Maintenance Regimen for Psoriasis Vulgaris

Phase: N/A Priority: Normal
NCT ID: NCT02899962 Org: User:
Start: 02/15/17 End: 06/26/19 Due: 06/26/20

Recombinant Human Antithrombin (ATryn®) in the Treatment of Patients With DIC Associated With Severe Sepsis

Phase: N/A Priority: Normal
NCT ID: NCT00506519 Org: User:
Start: 07/31/07 End: 03/31/09 Due: 03/31/10